Abstract 144P
Background
Paclitaxel is commonly used as second-line therapy in advanced gastric cancer (AGC). The decision to proceed with second-line chemotherapy and select a chemotherapy regimen may be critical in vulnerable AGC patients after progression with first-line chemotherapy. However, there are no predictive biomarkers to identify patients with AGC who benefit from paclitaxel-based chemotherapy.
Methods
This study included 288 patients with AGC receiving second-line paclitaxel-based chemotherapy between 2017 and 2022 from K-MASTER project, a nationwide, government-funded precision medicine initiative. The data included clinicogenomic factors: clinical (age [young-onset vs. others], sex, histology [intestinal vs. diffuse type], prior trastuzumab use, duration of first-line chemotherapy, etc.) and genomic factors (pathogenic or likely pathogenic variants). The data were randomly divided into training and test sets (0.8:0.2). Three machine-learning methods, including random forest (RF), logistic regression (LR), and artificial neural network with genetic embedding (ANN) models, were used to develop the prediction model and were validated in the test sets.
Results
The median age was 64 years (range, 25-91) and 65.6% were male. A total of 288 patients were divided into training (n=230) and test sets (n=58). There were no significant differences in baseline characteristics between training and test sets. In the training set, the AUC for prediction of progression-free survival (PFS) with paclitaxel-based chemotherapy was 0.51, 0.73, and 0.75 in RF, LR, and ANN models, respectively. In the test set, the Kaplan-Meier curves of PFS were separated according to the three models: 2.8 vs. 1.5 months (P=0.07) in RF, 2.3 vs. 6.5 months (P=0.07) in LR, and 2.1 vs. 7.6 months (P=0.02) in ANN models.
Conclusions
These machine-learning models integrated clinical and genomic factors and can guide the selection of patients with AGC with a greater likelihood of a benefit from second-line paclitaxel-based chemotherapy. Further studies are necessary to validate and update these models in independent datasets in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract